Email: sjl78@case.edu
Professor, Department of Pediatrics, School of Medicine
Professor, Department of Pharmacology, School of Medicine
Executive Committee Member, Functional Electrical Stimulation Center, School of Medicine
Associate Director, Functional Electrical Stimulation Center, School of Medicine
Additional Information
My past and current NIH/NIDA- and GSK-funded projects have fostered a multidisciplinary research program in ventilatory processing, and autonomic neurophysiology/neuropharmacology. We have published and hold patents on the use of L,D-thiolesters and L,D-thiolamides for opioid-induced respiratory depression and dependence/addiction (U.S. Patent Nos: 10,080,732, licensed by Atelerix Life Sciences; 10,080,732; 10,543,187; 10,881,633; 17/141,999; 17/742,040 and 17/696,204) I am a member of review Panels for NIDA and Department of Defense Congressionally Directed Medical Research Programs. Of relevance to my presentation today is our evidence that several of our novel L,D-thiolesters/L,D-thiolamides (1) prevent or reverse the adverse effects of opioids such as fentanyl on breathing, arterial blood gas (ABG) chemistry in rats while preserving analgesia, and (2) prevent and reverse physical dependence “addiction” and hyperalgesia to fentanyl and morphine in rats.
Areas of Research Interest
Development of novel therapeutic agents for treatment of cardiovascular/ventilatory disorders.
Central and peripheral regulation of the circulation and ventilatory system.
Neural and endothelial factors in hypertension.
Desensitization of G protein- and ion channel-coupled receptors.
Endothelial and neurogenic S-nitrosothiols.
Cardiac physiology, pharmacology and cell signaling.
Inflammatory and redox regulation of hemodynamic,ventilatory function.
Developmnet of drugs to reverse opioid-induced respiratory depression.
Developmnet of drugs to reverse opioid-induced addiction and dependence.
Academic Credentials: https://case.edu/medicine/pharmacology/people/stephen-lewis.